who we are
who we are
At IsoPlexis, big data meets cellular specificity: we find key differences among T-cells that drive response to therapy and disease
Our founding board and scientific advisory board bring together the best ideas in immunology & oncology from a nationwide ecosystem
Our cutting-edge technology and analytics platform shed a revealing light on the cell subsets responsible for patient outcomes
publications in peer reviewed journals
Highly Multiplexed Profiling of Single-cell Function Reveals Deep Functional Heterogeneity in Response to Pathogenic Ligands
Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
JAK-STAT Pathway Activation in Malignant and Non-Malignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Spring Mountain Capital
Spring Mountain Capital leads growth equity investment in IsoPlexis.
Stand up to Cancer
Groundbreaking analysis is helping advance therapeutic success.
Scientific Advisory Board
IsoPlexis appoints academic and industry experts to inaugural Scientific Advisory Board.